Remove Drug Development Remove Pharma Companies Remove Pharmaceuticals
article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. But not everyone in drug development is playing this game. No wonder investing in drug development is so hard! And that is easier said than done.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in STEM with Kristina Torfgard

Drug Target Review

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

article thumbnail

#Unshackled: The evolving definition of asset-centricity

DrugBaron

Over the next few years, the practice of asset-centric investing was honed through various iterations all designed to counter the inherent progression bias that damages returns in pharmaceutical R&D. Doing that allowed the creation of new tools that are appropriate to deploy much later in the pharmaceutical R&D process.

article thumbnail

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy

Alta Sciences

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

Drug repurposing is an approach that, while not new, has become popular in the last decade. Generic drugs are also an interesting case and are common targets for repurposing due to their established safety profiles and long market presence.

Drugs 71